Mebendazole and temozolomide in patients with newly diagnosed high-grade gliomas: results of a phase 1 clinical trial
Notes from the study:
Those taking Mebendazole for at least one month had a median progression-free survival of 13 months compared to 9 for the control group
2 patients are still alive and taking Mebednazole 6 years after the trial started